PL4200018T3 - Przeciwciała anty-par-2 i sposoby ich zastosowania - Google Patents
Przeciwciała anty-par-2 i sposoby ich zastosowaniaInfo
- Publication number
- PL4200018T3 PL4200018T3 PL21773918.4T PL21773918T PL4200018T3 PL 4200018 T3 PL4200018 T3 PL 4200018T3 PL 21773918 T PL21773918 T PL 21773918T PL 4200018 T3 PL4200018 T3 PL 4200018T3
- Authority
- PL
- Poland
- Prior art keywords
- par
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067259P | 2020-08-18 | 2020-08-18 | |
| PCT/US2021/046552 WO2022040345A1 (en) | 2020-08-18 | 2021-08-18 | Anti-par-2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4200018T3 true PL4200018T3 (pl) | 2025-06-02 |
Family
ID=77897712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21773918.4T PL4200018T3 (pl) | 2020-08-18 | 2021-08-18 | Przeciwciała anty-par-2 i sposoby ich zastosowania |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11725052B2 (pl) |
| EP (2) | EP4454659A3 (pl) |
| JP (1) | JP2023538379A (pl) |
| KR (1) | KR20230048439A (pl) |
| CN (1) | CN116761821B (pl) |
| AU (1) | AU2021328375A1 (pl) |
| CA (1) | CA3192208A1 (pl) |
| CL (1) | CL2023000494A1 (pl) |
| CO (1) | CO2023003208A2 (pl) |
| DK (1) | DK4200018T3 (pl) |
| ES (1) | ES3015472T3 (pl) |
| FI (1) | FI4200018T3 (pl) |
| HR (1) | HRP20250221T1 (pl) |
| HU (1) | HUE070287T2 (pl) |
| IL (1) | IL300660A (pl) |
| LT (1) | LT4200018T (pl) |
| MX (1) | MX2023002001A (pl) |
| PE (1) | PE20231187A1 (pl) |
| PL (1) | PL4200018T3 (pl) |
| PT (1) | PT4200018T (pl) |
| RS (1) | RS66573B1 (pl) |
| SI (1) | SI4200018T1 (pl) |
| SM (1) | SMT202500106T1 (pl) |
| TW (1) | TWI904217B (pl) |
| WO (1) | WO2022040345A1 (pl) |
| ZA (1) | ZA202302158B (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020225677A2 (en) * | 2019-05-03 | 2020-11-12 | Janssen Biotech, Inc. | Par2 modulation and methods thereof |
| LT4200018T (lt) * | 2020-08-18 | 2025-03-25 | Cephalon Llc | Anti-par-2 antikūnai ir jų panaudojimo būdas |
| GB202204159D0 (en) * | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| US20250282885A1 (en) * | 2022-05-04 | 2025-09-11 | Vst Bio Corporation | Compositions and methods for selective regulation of vascular permeability |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| CN120647762B (zh) * | 2025-06-16 | 2026-01-23 | 首都医科大学附属北京友谊医院 | 一种抗β1-AR-ECII抗体及其应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| EP1541682A3 (en) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DE69531148T2 (de) | 1994-01-31 | 2004-04-29 | Trustees Of Boston University, Boston | Bibliotheken aus polyklonalen antikörpern |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20080318960A1 (en) | 2005-05-26 | 2008-12-25 | Ethan Burstein | PAR2-modulating compounds and their use |
| US20070123508A1 (en) | 2005-05-27 | 2007-05-31 | Roger Olsson | PAR2-modulating compounds and their use |
| AU2007215304B2 (en) * | 2006-02-09 | 2012-06-14 | Alba Therapeutics Corporation | Formulations for a tight junction effector |
| US7888482B2 (en) | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| JP5933894B2 (ja) | 2007-09-14 | 2016-06-15 | アディマブ， エルエルシー | 合理的に設計された、合成抗体ライブラリおよびその使用 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP2011530515A (ja) | 2008-08-05 | 2011-12-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐａｒ−２活性化のエフェクターおよび炎症の調節におけるその使用 |
| WO2010085682A2 (en) | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| WO2010132954A1 (en) | 2009-05-21 | 2010-11-25 | Oral Health Australia Pty Ltd | Method of treating periodontal disease by administering antagonists of par-2 |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| KR102810907B1 (ko) | 2010-07-16 | 2025-05-21 | 아디맵 엘엘씨 | 항체 라이브러리 |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| WO2012010453A1 (en) | 2010-07-19 | 2012-01-26 | Dsm Ip Assets B.V. | Flame retardant insulated electrical wire |
| JP5883863B2 (ja) | 2010-07-28 | 2016-03-15 | ザ ユニバーシティ オブ クィーンズランド | プロテアーゼ活性化受容体の調節剤 |
| KR20140108520A (ko) * | 2011-10-14 | 2014-09-11 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | CD1d에 대한 항체 |
| EP2834270B1 (en) * | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
| GB201213700D0 (en) | 2012-08-01 | 2012-09-12 | Proximagen Ltd | Receptor antagnists II |
| KR102402451B1 (ko) | 2013-03-28 | 2022-05-26 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 미세유동 장치 및 분비물의 다세포 검정법에서의 그의 사용 방법 |
| WO2016005369A1 (en) | 2014-07-08 | 2016-01-14 | Celltrend Gmbh | Par2 antibodies for diagnosis of graft intolerance of a liver transplant |
| WO2016154075A1 (en) | 2015-03-20 | 2016-09-29 | Vertex Pharmaceuticals Incorporated | Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway |
| EP3538557A4 (en) * | 2016-11-08 | 2020-11-18 | Ablexis, LLC | ANTI-CD47 ANTIBODY |
| PT3596125T (pt) * | 2017-03-16 | 2025-11-27 | Medimmune Ltd | Anticorpos anti-par2 e suas utilizações |
| EP3749362A1 (en) | 2018-02-09 | 2020-12-16 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| LT4200018T (lt) * | 2020-08-18 | 2025-03-25 | Cephalon Llc | Anti-par-2 antikūnai ir jų panaudojimo būdas |
-
2021
- 2021-08-18 LT LTEPPCT/US2021/046552T patent/LT4200018T/lt unknown
- 2021-08-18 ES ES21773918T patent/ES3015472T3/es active Active
- 2021-08-18 DK DK21773918.4T patent/DK4200018T3/da active
- 2021-08-18 EP EP24190723.7A patent/EP4454659A3/en active Pending
- 2021-08-18 IL IL300660A patent/IL300660A/en unknown
- 2021-08-18 AU AU2021328375A patent/AU2021328375A1/en active Pending
- 2021-08-18 RS RS20250218A patent/RS66573B1/sr unknown
- 2021-08-18 KR KR1020237009394A patent/KR20230048439A/ko active Pending
- 2021-08-18 PL PL21773918.4T patent/PL4200018T3/pl unknown
- 2021-08-18 WO PCT/US2021/046552 patent/WO2022040345A1/en not_active Ceased
- 2021-08-18 PT PT217739184T patent/PT4200018T/pt unknown
- 2021-08-18 CA CA3192208A patent/CA3192208A1/en active Pending
- 2021-08-18 MX MX2023002001A patent/MX2023002001A/es unknown
- 2021-08-18 HR HRP20250221TT patent/HRP20250221T1/hr unknown
- 2021-08-18 JP JP2023512186A patent/JP2023538379A/ja active Pending
- 2021-08-18 US US17/405,275 patent/US11725052B2/en active Active
- 2021-08-18 CN CN202180068444.7A patent/CN116761821B/zh active Active
- 2021-08-18 FI FIEP21773918.4T patent/FI4200018T3/fi active
- 2021-08-18 SM SM20250106T patent/SMT202500106T1/it unknown
- 2021-08-18 SI SI202130279T patent/SI4200018T1/sl unknown
- 2021-08-18 PE PE2023000322A patent/PE20231187A1/es unknown
- 2021-08-18 EP EP21773918.4A patent/EP4200018B1/en active Active
- 2021-08-18 TW TW110130561A patent/TWI904217B/zh active
- 2021-08-18 HU HUE21773918A patent/HUE070287T2/hu unknown
-
2023
- 2023-02-17 CL CL2023000494A patent/CL2023000494A1/es unknown
- 2023-02-21 ZA ZA2023/02158A patent/ZA202302158B/en unknown
- 2023-03-15 CO CONC2023/0003208A patent/CO2023003208A2/es unknown
- 2023-06-21 US US18/338,946 patent/US12384841B2/en active Active
-
2025
- 2025-07-03 US US19/260,054 patent/US20260062478A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019709D0 (en) | Anti-Coronavirus antibodies and methods of use | |
| SG11202110145SA (en) | Antibodies against sars-cov-2 and methods of using the same | |
| SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
| SG11202108398YA (en) | Anti-claudin 18 antibodies and methods of use thereof | |
| HUE070287T2 (hu) | Anti-PAR-2 ellenanyagok és eljárások alkalmazásukra | |
| SG11202108403UA (en) | Anti-clec2d antibodies and methods of use thereof | |
| IL287282A (en) | Anti-mertk antibodies and methods of using them | |
| IL290741A (en) | Antibodies against cd-96 and methods of using them | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of using them | |
| IL316368A (en) | Anti-TL1A antibodies and methods of using them | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of using them | |
| IL315845A (en) | Anti-dectin-1 antibodies and methods of using them | |
| IL288886A (en) | Antibodies and methods of use | |
| ZA202208598B (en) | Isoform-selective anti-tgf-beta antibodies and methods of use | |
| IL317690A (en) | Anti-GPNMB antibodies and methods of using them | |
| IL318694A (en) | Antibodies against CCR8 and methods of using them | |
| IL308260A (en) | Antibodies against Tigit and methods of using them | |
| IL313265A (en) | Antagonistic antibodies against NPR1 and methods of using them | |
| EP4423138A4 (en) | Anti-CD47 antibodies and methods for using them | |
| IL308157A (en) | Antibodies against TIGIT, antibodies against CD96, and methods of using them | |
| ZA202105152B (en) | Anti-elastin antibodies and methods of use | |
| ZA202201160B (en) | Anti-grp78 antibodies and method of use thereof | |
| IL318357A (en) | ANTI-IL27R antibodies and methods of using them | |
| IL316700A (en) | ANTI-BMP9 antibodies and methods of using them | |
| IL316894A (en) | ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF |